AVAH (65) ADUS (74) WGS (47) OPCH (74) ⌘ Pro Terminal →

Privia Health Group Inc. (PRVA) — RQD Stock Rating Cockpit

$21.48 -2.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $21.35

Privia Health Group Inc. (PRVA) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $2.74B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRVA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PRVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Privia Health Group Inc. (NASDAQ: PRVA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $21.48 (-2.34% 1D, market cap $2.74B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, PRVA ranks #230 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PRVA compare to AVAH and ADUS in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), PRVA carries a Roarable D+ (53/100 RQD), trailing P/E of 122.6x, gross margin of —, and ROIC of 10.5%. By comparison, AVAH (Aveanna Healthcare Holdings Inc.) holds a C grade (65/100 RQD, P/E N/A, ROIC 15.7%, cap $2.87B) and ADUS (Addus HomeCare Corporation) posts a B grade (74/100 RQD, P/E 24.2x, ROIC 9.1%, cap $2.34B). Among the 5-stock peer group, OPCH leads on earnings multiple (23.0x) while AVAH leads on capital efficiency (15.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRVA?

▼

Per PRVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001759655), Privia Health Group Inc. generated $0 in revenue, $22.9M in net income, and $163.4M in free cash flow against $1.37B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $21.35 (-0.61%)🧬 Cannibal Buyback (-0.68% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 4.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-2.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRVA)Realized 20D OHLCV Swing Band: ±5.8%

Deterministic 5-Pillar Attribution (53/100 Composite)

🔍 WHY PRVA SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+14/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 4.1% FCF Margin ($163.4M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$21.65+5.9% Next Q

Q2 (-2Q)

Grade C$22.93-4.8% Next Q

Q3 (-1Q)

Grade C$21.83-1.6% Next Q

Current

Grade D+$21.48-0.9% Hist 90D α

Trajectory: C (61) → D+ (53)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRVA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRVA currently carries a cautious 53/100 (D+) rating due to Whale & Options Positioning (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($20.91) and Max Pain ($22.55) forces dealer call-delta covering toward $30.26.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-0.68% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRVA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PRVA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 53%NO 47%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

48.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

6 / 99-Pt Accounting

52-WEEK LASER RANGE26% OF RANGE

L: $19$21.48H: $29

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: B-RQD 14 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on PRVA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (70)

10.5% ROIC with 42.0% gross margin and 5.82% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (43)

17/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like PRVA

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Priced at 123x earnings—high expectations leave less room for a lukewarm quarter.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRVA)

✓Walkthrough of PRVA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRVA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.39%▼ DESCENDING CHANNEL

2026-11-03O $21.99H $21.99L $21.48C $21.48VOL 841.2K

RES: $22.38SUP: $18.28SMA50: $20.91SMA200: $22.65

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRVA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRVA Butterfly Map → + Track PRVA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRVA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRVA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRVA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRVA)

Health Care Rank #230 of 1016 ⚔️ AVAH vs PRVA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRVA vs. AVAH, ADUS, WGS, OPCH)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Privia Health Group Inc. (PRVA) ranks #230 by composite RQD confidence (53/100, grade D+) and #215 by equity capitalization ($2.74B). Within this direct 5-issuer industry benchmark cohort, OPCH leads on earnings valuation at 23.0x trailing P/E, while AVAH leads on capital efficiency and profitability with 15.7% ROIC and 33.3% gross margin. ADUS currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with PRVA at 53/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRVA ACTIVE Privia Health Group Inc.	D+	53/100	122.6x	—	10.5%	-2.34%	$2.74B	Benchmark Subject
AVAH Aveanna Healthcare Holdings Inc.	C	65/100	—	33.3%	15.7%	-0.75%	$2.87B	/avah-vs-prva →
ADUS Addus HomeCare Corporation	B	74/100	24.2x	32.5%	9.1%	+0.97%	$2.34B	/adus-vs-prva →
WGS GeneDx Holdings Corp. (Class A)	D	47/100	—	69.7%	-4.1%	-2.76%	$2.06B	/wgs-vs-prva →
OPCH Option Care Health Inc.	B	74/100	23.0x	19.3%	11.9%	-0.06%	$4.77B	/opch-vs-prva →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001759655

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Privia Health Group Inc. (PRVA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $22.9M, operating cash flow of $163.4M, and free cash flow of $163.4M (+49.5% YoY). On the balance sheet, PRVA closed FY2025 with $1.37B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$22.9M	$163.4M	$163.4M	$1.37B	—
FY2024 (FY)	2024-12-31	$0	$14.4M	$109.3M	$109.3M	$1.14B	—
FY2023 (FY)	2023-12-31	$0	$23.1M	$80.8M	$80.8M	—	—

3. PRVA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PRVA compare to AVAH and ADUS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PRVA?

Where is PRVA trading relative to its 50-day, 200-day, and 52-week technical levels?

PRVA last traded at $21.48 (-2.34% on volume of 841,180 shares), positioning the stock +2.73% above its 50-day simple moving average ($20.91) and -5.17% below its 200-day simple moving average ($22.65). Across its 52-week range of $18.92 to $28.82, PRVA sits at the 25.9% percentile with a 14-day RSI of 48.8 (NEUTRAL RANGE) and an implied next-earnings move of ±5.8% ($20.23 to $22.73).

PRVA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PRVA stock right now?

Privia Health Group Inc. (PRVA) currently earns a Roarable Rating of D+ (Sell — SELL) with 53/100 RQD Confidence. Stretched risk/reward at 123x P/E (11% return on capital) under elevated 10-year interest-rate pressure.

What is PRVA's 12-month price target and RQD AI Jury consensus?

PRVA's 12-month base price target is $21 (range $16.38 to $30.26), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PRVA RQD Cockpit PRVA 12M Forecast PRVA Earnings & Move PRVA Dividends & DRIP PRVA Insiders & 13F PRVA Whale Options PRVA Profit Sankey PRVA News & Why

ROARABLE RATING BRIEF • RQD 53/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PRVA — Privia Health Group Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:24:53Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PRVA scores 56 out of 100, a letter grade of D+, with the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine 14/20 (ROIC 10.5%; FCF yield 5.82%); Whale 13F Flow 10/20 (institutional accumulation and options positioning); Insider Conviction 10/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 9/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet 13/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). The strongest pillar is the cash engine, supported by a 10.5% ROIC and a 5.82% FCF yield, which provides the main upside case. The weakest pillars are macro fit and insider conviction, which indicate limited sector-relative tailwinds and little reported insider buying conviction. Against the market data, the stock trades at a P/E (TTM) of 122.6 and an EV/EBITDA of 68.1, so the valuation tradeoff is steep relative to reported earnings; the cash-flow yield is the offsetting feature. The verdict reflects the rating framework's conclusion, not a personalized recommendation.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
$22	$2.81B	122.6	114	68.1	0.18	0%	1.0	$18.92 - $28.82	10.5%

Business

Privia Health Group Inc. is a NASDAQ-listed issuer in the Health Care sector, Medical/Nursing Services industry, per the company profile. Beyond the sector and industry classification, the source data does not describe its products, customers, or revenue model. Revenue is reported as $0.0M in each period, so the source data does not establish how the company generates income in the reporting provided.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$34.2M	$22.9M	N/A	$163.4M	$479.7M	N/A
FY 2024	$0.0M	$17.0M	$14.4M	N/A	$109.3M	$491.1M	N/A
FY 2023	$0.0M	$20.6M	$23.1M	N/A	$80.8M	N/A	N/A

Per the SEC financials, operating income rose from $17.0M in FY 2024 to $34.2M in FY 2025, and free cash flow increased from $109.3M to $163.4M over the same period. Per the market data, gross, operating, and net margins are each reported as 0%, so margin analysis cannot be drawn from the source data. ROIC is 10.5% and the Altman Z-Score is 2.5 per the Roarable RQD rating, with a Piotroski F-Score of 6/9 and a Debt/Equity ratio of 0.5. Reported cash was $479.7M at FY 2025, and debt is not available in source data.

Open Questions

What are the company's revenue figures, given that reported revenue is $0.0M in every period?
What is the reported total debt, and how does it reconcile with the Debt/Equity ratio of 0.5?
What explains the gap between a P/E (TTM) of 122.6 and an EPS (TTM) of 0.18 relative to net income?
What drives the reported 0% gross, operating, and net margins, and is that a data-coverage issue?
Which institutional holders, insiders, or analysts (if any) are tracked for PRVA?

PRVA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Privia Health Group Inc. (PRVA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PRVA Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 16h ago

Privia Health Group, Inc. (PRVA) Stock Forecasts

Yahoo Finance report covering Privia Health Group Inc. (PRVA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 19h ago

Privia Health Group Inc (PRVA) Stock Up 3.3% and Still Undervalued -- GF Score: 83/100

GuruFocus report covering Privia Health Group Inc. (PRVA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 22h ago

Privia Health Group: Operating Leverage Could Lead To Share Price Upside (NASDAQ:PRVA)

Seeking Alpha report covering Privia Health Group Inc. (PRVA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

2 healthcare stocks with solid fundamentals and 1 we question

Yahoo Finance report covering Privia Health Group Inc. (PRVA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

More than 36,000 people are set to receive care through Privia's network in 2027.

Stock Titan report covering Privia Health Group Inc. (PRVA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Privia Health Group (PRVA) Renews Anthem Deal, Is The Stock Still Undervalued?

Simply Wall St report covering Privia Health Group Inc. (PRVA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Privia Health Group (PRVA) Rises 1.35% to $20.30, Holding Mid-Range Between Key Levels - Advance Decline Line

https://www.siam.in/ report covering Privia Health Group Inc. (PRVA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 17h ago

Privia Health Expands VBC Footprint with Acquisition of American Choice Healthcare MSSP Business

ARLINGTON, Va., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the acquisition of American Choice Healthcare MSSP, LLC (ACH), a wholly-owned subsidiary of Cano Health. The Accountabl

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRVA Bull vs. Bear Conversation Board — What's Your Call at $21.48?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRVA 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $23.76 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PRVA (D+ • RQD 56/100) a Buy at $22.00?

Welcome to the PRVA (Privia Health Group Inc.) Roar Pit. Current RQD Composite is 56/100 (Roarable Sell — Weak Fundamentals / Trim) in Medical/Nursing Services. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (122.6x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $16.50 (-25.0%)

Spot @ $22.00

Pump the brakes on PRVA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PRVA, but look at what you are paying: 122.6x trailing P/E with tightening sector spreads. Unless Privia Health Group Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $25.96 (+18.0%)

Spot @ $22.00

PRVA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PRVA, the market is fixating on short-term headline noise in Medical/Nursing Services and ignoring the balance sheet and cash flow trajectory. At $22.00 (52-wk range $18.92 - $28.82), any beat on forward guidance forces shorts and underweight funds to chase.